Pamela Munster

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Merck
    Topic:
    Clinical Trials
    Date added:
    09/29/2023
    Date updated:
    09/09/2024
    Relationship end date:
    04/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Amgen
    Topic:
    Clinical Trials
    Date added:
    09/29/2023
    Date updated:
    09/09/2024
    Relationship end date:
    04/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    genetech
    Topic:
    Clinical Trials
    Date added:
    09/29/2023
    Date updated:
    09/09/2024
    Relationship end date:
    04/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    GSK
    Topic:
    Clinical Trials
    Date added:
    09/29/2023
    Date updated:
    09/09/2024
    Relationship end date:
    04/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Revolution
    Topic:
    Clinical Trials
    Date added:
    09/29/2023
    Date updated:
    09/09/2024
    Relationship end date:
    04/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Seagen
    Topic:
    Clinical Trials
    Date added:
    09/29/2023
    Date updated:
    09/09/2024
    Relationship end date:
    04/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Johnson and Johnson
    Topic:
    Business consulting
    Date added:
    09/29/2023
    Date updated:
    09/09/2024
    Relationship end date:
    04/30/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Clovis
    Topic:
    Clinical trials
    Date added:
    09/29/2023
    Date updated:
    09/09/2024
    Relationship end date:
    04/01/2024
Return to 4th Binaytara Precision Oncology Summit: Current Standards and Emerging Therapies